Press Release Jun 15 2021
Filed with NSE · · 3 pages · English
Summary by 6ix AI
It informs stakeholders about Avenue's receipt of a Complete Response Letter from the FDA concerning IV tramadol. The letter indicates that the FDA does not support the drug's approval as a monotherapy for acute pain treatment.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Cipla
- Press Release May 24 2021
- Press Release May 20 2021
- Press Release May 14 2021
- Press Release May 10 2021
- Press Release May 05 2021
Later from Cipla
- Press Release Jun 23 2021
- Press Release Jun 29 2021
- Press Release Aug 05 2021
- Press Release Aug 12 2021
- Press Release Aug 25 2021
Follow Cipla into a list and get an email when it puts out news.
Follow Cipla